相关实验视频

Updated: Jun 9, 2025

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

β-碳-3-碳胺抗疟药:结构-活性关系,ADME-毒素研究和耐药性分析

Jopaul Mathew¹, Bo Zhou^1,2, Reagan S Haney³

¹Department of Chemistry and Virginia Tech Center for Drug Discovery, Virginia Tech, 1040 Drillfield Drive, Blacksburg, Virginia 24061, United States.

ACS infectious diseases

|October 28, 2024

概括

新的抗疟疾药物发现非常重要,因为寄生虫的耐药性正在上升. 研究人员合成了新型β-卡博林衍生物,识别了具有独特作用机制的强效化合物,对抗疟疾寄生虫.

科学领域:

药用化学医学化学
寄生虫学的寄生虫学
药物发现药物发现药物发现

背景情况:

由于寄生虫的耐药性,阿尔特米西宁组合治疗的有效性受到威胁.
迫切需要具有新作用机制的新型抗疟疾药物.
之前的研究发现β-卡博林1a在口服时对具有低交叉抗性的疟疾有效.

研究的目的:

合成和评估用于抗疟疾活动的新β-卡博林衍生物.
识别具有新作用机制的强效抗疟疾化合物.
评估有前途的衍生品的类似药物的特性和交叉耐药性.

主要方法:

合成了91种新的β-卡博林衍生物.
在体外抗疟疾评估针对Plasmodium falciparum菌株.
药物类似性质的评估和体外条形编码交叉电阻分析.

主要成果:

无性血阶段生长抑制数据显示,在C1位置偏好特定的基环.
化合物42a,一种3,4,5-三二替代衍生物,是最强效的,其疗效是化合物1a的两倍.
四种强效类型 (1a,1m,42a,42m) 对多种耐药突变没有交叉耐药性.

结论:

合成的β-卡博林衍生物显示出显著的抗疟疾潜力.
化合物42a及其类型代表了新的抗疟疾药物开发的有希望的线索.
观察到的缺乏交叉电阻表明了这种化合物类别的新作用机制.

关键词:

在ADME-Tox中使用了ADME-Tox.它具有抗感染作用.疟疾疟疾是一种疾病.阻力配置文件的阻力配置文件小分子抑制剂小分子抑制剂

更多相关视频

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Assays for the Identification of Novel Antivirals against Bluetongue Virus

Published on: October 11, 2013

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...